The development and implementation of Artificial Intelligence (AI) health systems represent a great power that comes with great responsibility. Their capacity to improve and transform healthcare involves inevitable risks. A major risk in this regard is the propagation of bias throughout the life cycle of the AI system, leading to harmful or discriminatory outcomes. This paper argues that the European medical device regulations may prove inadequate to address this-not only technical but also social challenge. With the advent of new regulatory remedies, it seems that the European policymakers also want to reinforce the current medical device legal framework. In this paper, we analyse different policies to mitigate bias in AI health systems included in the Artificial Intelligence Act and in the proposed European Health Data Space. As we shall see, the different remedies based on processing sensitive data for such purpose devised by the European policymakers may have very different effects both on privacy and on protection against discrimination. We find the focus on mitigation during the pre-commercialisation stages rather weak, and believe that bias control once the system has been implemented in the real world would have merited greater ambition.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/bioe.13398 | DOI Listing |
Int Dent J
March 2025
Department of Restorative Dentistry, College of Dentistry, Ajman University, Ajman, United Arab Emirates; Centre of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates.
Artificial intelligence (AI) holds immense promise in revolutionising dentistry, spanning, diagnostics, treatment planning and educational realms. This narrative review, in two parts, explores the fundamentals and the multifaceted potential of AI in dentistry. The current article explores the profound impact of AI in dentistry, encompassing diagnostic tools, treatment planning, and patient care.
View Article and Find Full Text PDFJ Clin Neurosci
March 2025
Department of Obstetrics and Gynecology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan; Department of Obstetrics and Gynecology, Koga Red Cross Hospital, 1150 Shimoyama, Koga, Ibaraki 306-0014, Japan; Medical Examination Center, Ibaraki Western Medical Center, 555 Otsuka, Chikusei, Ibaraki 308-0813, Japan. Electronic address:
J Gastroenterol Hepatol
March 2025
Department of Radiology, Yunnan Cancer Center, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
This review provides an in-depth exploration of the evolving role of immunotherapy in gastrointestinal (GI) cancers, with a particular focus on immune checkpoint inhibitors (ICIs) and their associated predictive biomarkers. We present a detailed analysis of established biomarkers, such as PD-L1, microsatellite instability (MSI), tumor mutational burden (TMB), and the tumor microenvironment (TME), as well as emerging biomarkers, including gut microbiota and Epstein-Barr virus (EBV). The predictive value of these biomarkers in guiding clinical decision-making and optimizing immunotherapy outcomes is thoroughly discussed.
View Article and Find Full Text PDFAcute Crit Care
February 2025
Division of Pulmonary, and Critical Care Medicine, Department of Internal Medicine, Pusan National University Hospital, Busan, Korea.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!